j
u
r
n
l
p
r
e
p
r
f
beyond
wellknown
antiparasit
activ
chloroquin
hydroxychloroquin
hcq
antibacteri
antifung
antivir
properti
latter
hepat
b
c
human
immunodefici
viru
influenza
certain
herp
virus
report
gautret
et
al
treatment
patient
hcq
may
rapidli
reduc
viral
load
strategi
could
potenti
prove
harm
patient
especi
minim
symptomat
diseas
hcq
could
limit
durat
exposur
immun
system
viru
addit
immunosuppress
effect
rational
use
patient
autoimmun
diseas
azithromycin
anoth
antibiot
combin
hcq
treatment
immunomodulatori
antiinflammatori
properti
use
sever
respiratori
diseas
howev
larg
prospect
placebocontrol
studi
evalu
use
allogen
hematopoiet
cell
transplant
recipi
stop
earli
higher
rate
relaps
hematolog
malign
azithromycin
arm
perspect
antivir
immun
robust
immun
respons
requir
healthi
immun
system
adequ
durat
exposur
viru
thu
immun
respons
immunosuppress
patient
suboptim
absenc
effect
vaccin
collect
immun
socal
herd
immun
propos
populationlevel
strategi
manag
pandem
countri
impos
lockdown
attempt
flatten
pandem
curv
give
health
system
time
build
capac
ultim
allow
progress
develop
herd
immun
apart
cardiovascular
sideeffect
widespread
use
hcq
azithromycin
could
detriment
patient
minim
symptomat
diseas
immun
respons
may
insuffici
even
absent
patient
receiv
hcq
without
azithromycin
especi
combin
given
begin
diseas
cours
patient
would
remain
risk
contract
diseas
respons
failur
lockdown
strategi
figur
follow
first
french
report
use
hcq
patient
use
antimalari
remain
controversi
despit
lack
proven
efficaci
may
countri
includ
develop
nation
proceed
use
agent
given
concern
prioriti
given
urgent
assess
cellular
humor
immun
patient
alreadi
receiv
antimalari
drug
healthcar
commun
commit
indiscrimin
use
minim
asymptomat
individu
